| Patient | Sex | BMI kg·m−2 | Duration of SXT treatment days | Total treatment duration days | Ethnicity | Comorbidities and intoxications | Localisation of TB | Other anti-TB drugs# |
| 1 | M | 18.6 | 531 | 546 | Asian | Smoking, soft drugs | Pulmonary | E, AM, MOX, PTH, LZD, CFZ, Doxy |
| 2 | F | 21.5 | 191¶ | 202¶ | African | None | Pulmonary and extrapulmonary | MOX, KM, ERTA |
| 3 | M | 22.1 | 501 | 705 | Russian | Alcohol abuse | Pulmonary | Z, KM, LZD, CFZ, CLM, CM |
| 4 | F | 18.1 | 412 | 548 | Asian | None | Pulmonary | E, AM, MOX, PTH, LZD, CFZ, CPX |
| 5 | F | 19.3 | 154 | 191 | Russian | None | Pulmonary | MOX, LZD, AMX/CL, ERTA |
| 6 | M | 20.7 | 350 | 365 | Asian | Smoking | Pulmonary | E, AM, MOX, LZD, CFZ, CPX, Doxy |
| 7 | F | 27.2 | 453 | 566 | African | None | Pulmonary | AM, MOX, CS, LZD |
| 8 | F | 31 | 52 | 55 | African | Diabetes mellitus | Extrapulmonary | AM, KM, MOX, LZD, CLM, ERTA |
| 9 | M | 19.0 | 56 | 62 | Russian | Alcohol abuse, drug abuse, smoking | Pulmonary | MOX, LZD, CLM, ERTA |
| 10 | M | 21.1 | 41¶ | 44¶ | African | None | Extrapulmonary | CLM, ERTA, LZD, KM |
Data are presented as n, unless otherwise stated. BMI: body mass index; M: male; F: female; E: ethambutol; AM: amikacin; MOX: moxifloxacin; PTH: protionamide; LZD: linezolid; CFZ: clofazimine; Doxy: doxycycline; KM: kanamycin; ERTA: ertapenem; Z: pyrazinamide; CLM; clarithromycin; CM: capreomycin; CPX: ciprofloxacin; AMX/CL: amoxicillin + clavulanic acid (Augmentin); CS: cycloserine. #: taken at any time during MDR-TB treatment; ¶: patient still receiving treatment.